BEIJING ENT (00392) has announced measures to enhance its corporate governance framework. The responsibilities of the Nomination Committee have been revised to incorporate corporate governance duties. Reflecting this expanded scope, the committee has been renamed the "Nomination and Governance Committee," effective April 28, 2026. To better align long-term strategic planning with investment decisions, the responsibilities of the Investment Committee have been revised to include strategic duties. Consequently, it has been renamed the "Strategy and Investment Committee," also effective April 28, 2026. Mr. Xiong Bin, Mr. Xu Tong, and Mr. Dong Huanzhang have been appointed as members of the Strategy and Investment Committee. Mr. Yang Zhichang has stepped down from his roles as member and chairman of this committee due to other commitments, with Mr. Xiong Bin succeeding him as chairman. These changes take effect on April 28, 2026. A Legal and Compliance Committee was established under the board of directors on April 28, 2026. This committee consists of five directors, including three executive directors: Mr. Xiong Bin (chairman), Mr. Geng Chao, and Mr. Dong Huanzhang; one non-executive director, Mr. Su Junjie; and one independent non-executive director, Ms. Chen Manqi. A Sustainable Development Committee was also established under the board on the same date. It is composed of five directors, including two executive directors: Mr. Xiong Bin (chairman) and Mr. Dong Huanzhang; two non-executive directors, Mr. Yu Xijian and Mr. Su Junjie; and one independent non-executive director, Mr. Wu Jiesi. Due to other commitments, Mr. Yang Zhichang has resigned from the Remuneration Committee. The board has appointed Mr. Xiong Bin as a member of the Remuneration Committee, effective April 28, 2026. Following this change, the Remuneration Committee comprises three directors: one executive director, Mr. Xiong Bin, and two independent non-executive directors, Mr. Wu Jiesi (chairman) and Mr. Lin Haihan.
Comments